...that paragraph to me is more about the beneficial effect + outcome in early MPC treatment on limiting deleterious scar tissue replacement and subsequent reduction in LVEF rather than a description of specific MOA. I am intrigued by his reference to endothelium controlled signal pathways, disruption of which between endothelium and cardiocytes "has been implicated" in cardiac structural/functionsl abnormalities.
I guess I'm curious about MPC cardiac regenerative effects as well as immunomodulatory inflammatory effects that impede scar tissue + general degradation in myocardial function, control of which by itself may explain the beneficial results observed.
Nice. Thanks. More reading to do.
MSB's year is upon us. Strap in.
...that paragraph to me is more about the beneficial effect +...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.010(0.92%) |
Mkt cap ! $1.233B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.11 | $1.05 | $5.002M | 4.632M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5697 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
-0.010 ( 0.10 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.11 | $1.06 | 1181223 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| MSB (ASX) Chart |